Tag : HSCT

CONFERENCE UPDATE

Post-HSCT gilteritinib resumption improves OS in R/R FLT3mut+ AML: Pooled analysis of the phase 3 ADMIRAL and COMMODORE trials
Gilteritinib resumption post-hematopoietic stem cell transplantation (HSCT) improved overall survival (OS) in relapsed/refractory FMS-like tyrosine kinase 3-mutated acute myeloid leukemia (R/R FLT3mut+ AML) in a pooled analysis of ADMIRAL and COMMODORE, with landmark data suggesting reduced relapse or death in relapse-free day-60 HSCT patients.
CONFERENCE UPDATE

Personalized decision-support system refines timing of allogeneic-HSCT in CMML
A decision-support system refines the timing of allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myelomonocytic leukemia. By utilizing the International CMML Prognostic Scoring System (iCPSS), patient selection is enhanced and survival outcomes improved.